angiotensin receptor blocker + diuretic + 25oh vitamin d3 + statin

This drug combination is a standardized antiproteinuric medical regimen utilized as the control arm and baseline therapy in the DERENEDIAB clinical trial (NCT01842412), sponsored by Assistance Publique - Hôpitaux de Paris. The regimen is specifically designed for patients with type 2 diabetes, diabetic nephropathy, and persistent proteinuria. It consists of four pharmacological components: an angiotensin receptor blocker (specifically irbesartan at 300mg), a diuretic (either furosemide 40mg or indapamide LP 1.5mg, adjusted based on the patient's estimated glomerular filtration rate), 25-hydroxyvitamin D3 (calcifediol), and a statin (specifically atorvastatin 20mg). This multi-targeted approach aims to optimize blood pressure control, reduce intraglomerular pressure, provide renal anti-inflammatory effects, and manage dyslipidemia to slow the progression of kidney disease and reduce proteinuria.

Other names

angiotensin receptor blocker + diuretic + 25oh vitamin d3 + statin-Assistance Publique - Hôpitaux de Paris-diabetic nephropathy-proteinuriaStandardized antiproteinuric medication regimenDERENEDIAB regimen